Table 1.
Baseline characteristics of the patients.
| Variables | TACE-sorafenib-thermal ablation (n=22) | TACE-sorafenib (n=28) | P |
|---|---|---|---|
| Sex | >0.999* | ||
| Female | 0 | 1 (3.6%) | |
| Male | 22 (100%) | 27 (96.4%) | |
| Age (years) | 46.4 ± 11.9 | 48.8 ± 12.3 | 0.479 |
| <50 | 15 (68.2%) | 15 (53.6%) | 0.295 |
| ≥50 | 7 (31.8%) | 13 (46.4%) | |
| HBV infection | >0.999* | ||
| Positive | 22 (100%) | 27 (96.4%) | |
| Negative | 0 | 1 (3.6%) | |
| AFP (ng/ml) | 0.522 | ||
| <400 | 9 (40.9%) | 9 (32.1%) | |
| ≥400 | 13 (59.1%) | 19 (67.9%) | |
| Child-Pugh grade | 0.246* | ||
| A | 22 (100%) | 25 (89.3%) | |
| B | 0 (0%) | 3 (10.7%) | |
| BCLC stage | 0.749* | ||
| A | 4 (18.2%) | 3 (10.7%) | |
| B | 6 (27.3%) | 8 (28.6%) | |
| C | 12 (54.5%) | 17 (60.7%) | |
| Tumor diameter (cm) | 12.3 ± 2.5 | 12.3 ± 2.4 | 0.988 |
| Tumor number | 1.82 ± 0.8 | 1.96 ± 1.0 | 0.559 |
| 1 | 9 (40.9%) | 13 (46.4%) | 0.696 |
| 2–3 | 13 (59.1%) | 15 (53.6%) | |
| Growth pattern | 0.481* | ||
| Infiltrative | 5 (22.7%) | 4 (14.3%) | |
| Noninfiltrative | 17 (77.3%) | 24 (85.7%) | |
| Vascular invasion | 0.449 | ||
| Present | 11 (50.0%) | 11 (39.3%) | |
| Absent | 11 (50.0%) | 17 (60.7%) |
*The Fisher exact test was used.